A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 29, Issue 2, 2002, Pages 137-143

  Park, S H ^a   Lee, M H ^a   Lee, H ^a   Kim, H S ^a   Kim, K ^a   Kim, W S ^a   Jung, C W ^a   Im, Y H ^a   Yoon, S S ^a   Kang, W K ^a   Park, K ^a   Park, C H ^a   Kim, S W ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Hematopoietic stem cell transplantation; Heparin; Ursodiol; Veno occlusive disease

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; HEPARIN; MELPHALAN; METHYLPREDNISOLONE; THIOTEPA; URSODEOXYCHOLIC ACID;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LEUKEMIA; LIVER VENOOCCLUSIVE DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 85047696457     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703342     Document Type: Article

References (26)

1. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
2. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation
3. Venoocclusive disease of the liver following bone marrow transplantation
4. Venoocclusive disease of the liver after bone marrow transplantation: Diagnosis, incidence, and predisposing factors
5. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules
6. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation
7. Regimen-related toxicity in patients undergoing bone marrow transplantation
8. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: Retrospective analysis of 137 cases at a single institution
9. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia
10. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study of 136 children
11. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial
12. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
13. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
14. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients
15. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation
16. The Japanese multi-center open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation
17. A pilot study of continuous infusion heparin for the prevention of hepatic venocclusive disease after bone marrow transplantation
18. The syndrome of hepatic veno-occlusive disease after marrow transplantation
19. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation
20. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation
21. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients
22. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation
23. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation
24. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation
25. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation
26. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: A prospective randomized trial